XCSE
BRAINP
Market cap9mUSD
Apr 07, Last price
0.06DKK
1D
18.80%
1Q
-40.48%
IPO
-98.73%
Name
Brain+ A/S
Chart & Performance
P/E
—
P/S
26.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-17.14%
Revenues
2m
-27.23%
Net income
-19m
L+97.58%
CFO
-14m
L+240.52%
Earnings
May 22, 2025
Profile
Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer's. In addition, it develops an interface for clinicians to track and trace the patient's treatment progress. The company was incorporated in 2012 and is based in Copenhagen, Denmark. Brain+ A/S was formerly a subsidiary of Brain+ Holding ApS.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 2,352 -27.23% | 3,233 -19.03% | |||||||
Cost of revenue | 3,921 | (11,095) | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,569) | 14,327 | |||||||
NOPBT Margin | 443.21% | ||||||||
Operating Taxes | (628) | (1,435) | |||||||
Tax Rate | |||||||||
NOPAT | (941) | 15,762 | |||||||
Net income | (19,125) 97.58% | (9,680) 36.72% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 17,294 | 6,396 | |||||||
BB yield | -227.93% | -20.00% | |||||||
| Debt | |||||||||
Debt current | (2,735) | ||||||||
Long-term debt | |||||||||
Deferred revenue | 18,691 | 21,353 | |||||||
Other long-term liabilities | 594 | 546 | |||||||
Net debt | (3,091) | (9,137) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (13,707) | (4,025) | |||||||
CAPEX | (3,513) | (5,024) | |||||||
Cash from investing activities | (3,513) | (5,024) | |||||||
Cash from financing activities | 13,910 | 5,458 | |||||||
FCF | (2,240) | 5,440 | |||||||
| Balance | |||||||||
Cash | 3,091 | 6,402 | |||||||
Long term investments | |||||||||
Excess cash | 2,974 | 6,240 | |||||||
Stockholders' equity | (12,226) | 16,383 | |||||||
Invested Capital | 43,895 | 29,306 | |||||||
ROIC | 77.17% | ||||||||
ROCE | 40.31% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 39,112 | 18,703 | |||||||
Price | 0.19 -88.65% | 1.71 -50.00% | |||||||
Market cap | 7,588 -76.27% | 31,982 17.14% | |||||||
EV | 4,496 | 22,844 | |||||||
EBITDA | 2,366 | 15,955 | |||||||
EV/EBITDA | 1.90 | 1.43 | |||||||
Interest | 47 | ||||||||
Interest/NOPBT | 0.33% | ||||||||